Angiodynamics (ANGO) Other Accumulated Expenses (2012 - 2026)

Angiodynamics (ANGO) has 13 years of Other Accumulated Expenses data on file, last reported at $4.3 million in Q2 2026.

• Quarterly Other Accumulated Expenses fell 41.87% year-over-year to $4.3 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $4.3 million (down 41.87% YoY) and the FY2026 annual result came in at $4.3 million, down 41.87% from the prior year.
• Other Accumulated Expenses slipped to $4.3 million in Q2 2026, from $4.7 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $10.3 million in Q1 2024 to a low of $1.8 million in Q4 2023.
• A 5-year average of $5.0 million and a median of $4.5 million in 2026 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses surged 408.79% — and 2025, when it plunged 43.88%.
• Tracing ANGO's Other Accumulated Expenses over 5 years: stood at $2.6 million in 2022, then tumbled by 31.83% to $1.8 million in 2023, then surged by 408.79% to $9.0 million in 2024, then fell by 25.08% to $6.7 million in 2025, then sank by 36.09% to $4.3 million in 2026.
• The last three Other Accumulated Expenses figures came in at $4.3 million (Q2 2026), $4.7 million (Q1 2026), and $6.7 million (Q4 2025), per Business Quant data.